D DBV Technologies SA
D
Nyitva
2.826 -1.26
Áttekintés
Árfolyamváltozás megosztása
24 óra
Minimum
2.766
Maximum
2.872
Bevétel | -2.4M -48M |
|---|---|
Egy részvényre jutó nyereség | -0.095 |
Profit margin | -1,323.179 |
Munkavállalók | 161 |
EBITDA | -4.1M -46M |
Ajánlások | Semleges |
|---|---|
12 hónapos előrejelzés | +13.59% upside |
Következő eredményjelentés | 2026. júl. 29. |
|---|
Piaci kapitalizáció | -189M 851M |
|---|---|
Előző nyitás | 4.09 |
Előző zárás | 2.826 |
DBV Technologies SA Chart
A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.
Rólunk DBV Technologies SA
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.